Showing 1 - 10 of 23,504
The efficiency of Turkish health system, which was restructured by the health transformation framework, depends on the mutual compliance of both health service providers and demanders. The future and success of the new health system may be determined by solving problems that were generated from...
Persistent link: https://www.econbiz.de/10011259508
Public technology assessments in general and Comparative Effectiveness Research (CER) in particular have been justified by offsetting benefits of improving patient health and reducing health care spending. However, little conceptual and empirical understanding exists concerning the quantitative...
Persistent link: https://www.econbiz.de/10008628342
I farmaci innovativi ad alto costo ci fanno toccare con mano quali potranno essere i dilemmi della sanità futura se non si completano le riforme della governance di questo capitolo complesso della spesa pubblica (non solo federalismo, ma sistemi contabili e di reporting, schemi di...
Persistent link: https://www.econbiz.de/10010752623
This review discusses the role of consumer-directed and physician-directed promotion in the pharmaceutical market, based on the classic conceptual framework of whether such promotion is "persuasive" and/or "informative". Implications for public health and welfare partly depend on whether, and to...
Persistent link: https://www.econbiz.de/10010950788
This paper examines the impact of universal, free, and easily accessible primary healthcare on population health as measured by age-specific birth and mortality rates, focusing on a nationwide socialized medicine program implemented in Turkey. The Family Medicine Program (FMP), launched in 2005,...
Persistent link: https://www.econbiz.de/10011345385
Increased health care spending has been argued to be largely due to technological change. Cost-effectiveness analysis is the main tool used by private and public third-party payers to prioritize adoption of the new technologies responsible for this growth. However, such analysis by payers...
Persistent link: https://www.econbiz.de/10004991965
In the United States, drug safety and efficacy are primarily regulated by the Food and Drug Administration (FDA) and the legal system, which gives manufacturers large incentives to produce safe drugs and provide proper warnings for side effects, since patients can sue manufacturers that provide...
Persistent link: https://www.econbiz.de/10005084722
This paper examines the impact of universal, free, and easily accessible primary healthcare on population health as measured by age-specific birth and mortality rates, focusing on a nationwide socialized medicine program implemented in Turkey. The Family Medicine Program (FMP), launched in 2005,...
Persistent link: https://www.econbiz.de/10011337077
This paper examines the tradeoffs of monitoring for wasteful public spending. By penalizing unnecessary spending, monitoring improves the quality of public expenditure and incentivizes firms to invest in compliance technology. I study a large Medicare program that monitored for unnecessary...
Persistent link: https://www.econbiz.de/10014337803
Moral hazard and provider-induced demand may contribute to overutilization of scarce health care resources. The U.S. health care system includes several compensatory cost-containment mechanisms, but their effects depend on how patients and providers respond. We investigate hospice programs'...
Persistent link: https://www.econbiz.de/10014372448